YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...